Gefitinib (IRESSA, ZD 1839) for Non-Small Cell Lung Cancer (NSCLC): Recents results and further strategies

Advances in Experimental Medicine and Biology

Volumn 532, Issue , 2003, Pages 247-252

  Manegold, C ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEFITINIB; GEMCITABINE; PACLITAXEL; PLACEBO;

ACNE; ANTINEOPLASTIC ACTIVITY; ASTHENIA; CANCER CHEMOTHERAPY; CARCINOMA CELL; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TOXICITY; DRY SKIN; HISTOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MOUTH CARCINOMA; NAUSEA; PRIORITY JOURNAL; PRURITUS; RASH; SIDE EFFECT; SOLID TUMOR; TREATMENT OUTCOME; VOMITING;

EID: 0141757356     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-0081-0_20     Document Type: Conference Paper

References (14)

1. Douillard JY, Giaccone G, Horai T et al: Improvement in disease-related symptoms and quality of life in patients with advanced non-small cell lung cancer treated with ZD1839 (IRESSA) (IDEAL 1). Proc ASCO 299a (abstr. 1195), 2002
2. Fukuoka M, Yano S, Giaccone G et al: Final results from a phase II trial of ZD1839 (IRESSA) for patients with advanced non-small cell lung cancer (IDEAL 1). Proc ASCO 21, 298a (abstr. 1188), 2002
3. Giaccone G, Johnson DH, Manegold C et al: A phase III clinical trial of ZD1839 (IRESSA) in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small cell lung cancer (INTACT 1). Ann Oncol 13 (suppl. 5), 2 (abstr. 4 O), 2002.
4. Gonzalez-Larriba J, Giaccone G, van oosterom AT et al. ZD 1839 ("Iressa") in combination with gemcitabine in chemonaive patients with advanced solid tumors: final results of a phase I trial. Proc Am Soc Clin Oncol; 21:95a (A376), 2002.
5. Johnson DH, Herbst R, Giaccone G et al: ZD1839 (IRESSA) in combination mit paclitaxel and carboplatin in chemotherapy-naive patients with advanced non-small cell lung cancer: results from a phase III clinical trial (INTACT 2). Ann Oncol 13 (suppl. 5), 127 (abstr. 468 O), 2002
6. Kris M, Natale RB, Herbst T et al: A phase II trial of ZD1839 (IRESSA) in advanced non-small cell lung cancer patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Proc ASCO 21, 292a (abstr. 1166), 2002
7. Kris M, Herbst R, Rischin D et al. Objective regressions in non-small cell lung cancer patients treated in phase I trials of oral ZD 1839 ("Iressa"), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR). Lung Cancer; 29 (suppl 1): 72 (A233), 2000.
8. Manegold C, Gatzemeier U, Averbuch S, et al. An open label pilot trial of two doses of ZD 1839 ("Iressa") in combination with docetaxel in patients with advanced or metastatic non-small cell lung cancer (NSCLC); Preliminary results. Ann Oncol 2002; 13 (Suppl 5): 149a (Abstract 545)
9. Miller VA, Johnson D, Heelan RT et al. A pilot trial demonstrates the safety of ZD 1839 («Iressa») an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with carboplatin © and paclitaxel (P) in previously untreated advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 20326a (A1301), 2001.
10. Natale RB, Skarin A, Maddaox AM et al: Improvement in symptoms and quality of life for advanced non-small cell lung cancer patients receiving ZD1839 (IRESSA) in IDEAL 2. Proc ASCO 21, 292a (abstr. 1167), 2002
11. Negoro S, Nakagawa K, Fukuoka M et al. Final results of a phase I intermittent dose -escalation trial of ZD 1839 ("Iresssa") in Japanese patients with various solid tumors. Proc Am Soc Clin Oncol;20:324 (A1292), 2001.
12. Ranson M, Hammond L, Ferry D et al. ZD 1839 ("Iressa"), a selective oral EGFR-TKI (epidermal growth factor receptor tyrosine kinase inhibitor) is well tolerated and active in patients with solid. Malignant tumors:results pf a phase I trial. J Clin Oncol; 20:2240-2250, 2002.
13. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med., 346:92-98, 2002
14. Wells A. The epidermal growth factor receptor (EGFR) - a new target in cancer therapy. Signal 1:4-11, 2000